Research graph
References from Infused CD34+ cell dose predicts response to stem cell boost in children with poor graft function following allogeneic hematopoietic stem cell transplantation: a multicenter study from the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC). Local targets link to admitted publications; unresolved targets remain external evidence.
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
10.1038/s41409-024-02248-9 · 2024 · External reference
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
10.1038/s41409-024-02251-0 · 2024 · External reference
Graft failure in the modern era of allogeneic hematopoietic SCT
10.1038/bmt.2012.239 · 2012 · External reference
Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
10.1016/j.bbmt.2013.07.014 · 2013 · External reference
Graft Failure
2024 · External reference
Poor graft function after allogeneic hematopoietic stem cell transplantation—an old complication with new insights☆
10.1053/j.seminhematol.2018.08.004 · 2019 · External reference
Advances in the understanding of poor graft function following allogeneic hematopoietic stem-cell transplantation
10.1177/2040620720948743 · 2020 · External reference
10.1016/j.jtct.2021.04.007
10.1016/j.jtct.2021.04.007 · 2021 · External reference
Graft Failure after Allogeneic Hematopoietic Cell Transplantation
10.1016/j.bbmt.2007.10.025 · 2008 · External reference
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
10.1016/j.jtct.2021.07.012 · 2021 · External reference
Evaluation of risk factors for and subsequent mortality from poor graft function (PGF) post allogeneic stem cell transplantation
10.1080/10428194.2021.1872072 · 2021 · External reference
Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation
10.1016/j.bbmt.2019.05.036 · 2019 · External reference
Definitions, incidence and outcome of poor graft function after hematopoietic cell transplantation: A systematic review and meta-analysis
10.1016/j.blre.2023.101076 · 2023 · External reference
Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation
10.1182/bloodadvances.2021004537 · 2022 · External reference
Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation
10.1007/s00277-019-03715-w · 2019 · External reference
Poor graft function after T cell-depleted allogeneic hematopoietic stem cell transplant
10.1080/10428194.2020.1789622 · 2020 · External reference
Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis
10.1038/bmt.2016.98 · 2016 · External reference
Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients
10.1016/s0301-472x(99)00076-4 · 1999 · External reference
Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation
10.3389/fimmu.2022.911174 · 2022 · External reference
Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after allogeneic haematopoietic cell transplantation and other T-cell-engaging therapies
10.1016/s1473-3099(25)00069-6 · 2025 · External reference
Definitions matter: Multicenter investigation of incidence and outcome of poor graft function after hematopoietic cell transplantation
10.1002/hem3.70059 · 2024 · External reference
Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies long-term responders
10.1038/sj.bmt.1705072 · 2005 · External reference
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant
10.1016/j.bbmt.2019.05.023 · 2019 · External reference
CD34+ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation
10.1111/bjh.15012 · 2018 · External reference
Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study
10.3727/096368912x661319 · 2014 · External reference
Outcomes Following Second Allogeneic Stem Cell Transplant for Graft Failure or Poor Graft Function: A Single Centre Experience
10.1007/s12015-025-10903-x · 2025 · External reference
Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation
10.1038/sj.bmt.1705760 · 2007 · External reference
CD34+-Selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies
10.1016/j.bbmt.2013.11.034 · 2014 · External reference
Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function
10.3324/haematol.2019.226340 · 2020 · External reference
CD34+-selected stem cell “Boost” for poor graft function after allogeneic hematopoietic stem cell transplantation
2019 · External reference
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Th…
10.1016/j.jtct.2021.04.007 · 2021 · External reference
Documentation of Engraftment and Chimerism After HCT
2024 · External reference
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
10.1016/j.bbmt.2015.09.001 · 2016 · External reference
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
10.1016/j.bbmt.2014.12.001 · 2015 · External reference
CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation
10.1016/j.bbmt.2014.05.016 · 2014 · External reference
Autoimmune neutropenia: a rare complication of allogeneic hematopoietic stem cell transplantation?
10.3389/fimmu.2025.1640546 · 2025 · External reference
Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transpla…
10.1016/j.jtct.2024.03.019 · 2024 · External reference
CD34+-selected stem cell “Boost” for poor graft function after allogeneic hematopoietic stem cell transplantation
2019 · External reference
Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function
10.3324/haematol.2019.226340 · 2020 · External reference
CD34+ selected peripheral blood Stem Cell Boost (SCB) for Poor Graft Function (PGF) or mixed chimerism in pediatric patients, after hematopoietic stem cell transplantation: Results of a retrospective multicenter study
10.1111/petr.13909 · 2021 · External reference
Durable Engraftment and Excellent Overall Survival After CD34-Selected Peripheral Blood Stem Cell Boost in Pediatric Patients With Poor Graft Function Following Allogeneic Stem Cell Transplantation
10.1016/j.jtct.2022.09.027 · 2023 · External reference
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone
10.1038/bmt.2013.80 · 2013 · External reference
Transplanted CD34 + Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma
10.1016/j.bbmt.2010.11.021 · 2011 · External reference
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: Consensus guidelines and recommendations
10.1016/j.bbmt.2013.10.013 · 2014 · External reference
Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: Guidelines from the american society for blood and marrow transplantation
10.1016/j.bbmt.2014.05.003 · 2014 · External reference
Use of eltrombopag for the treatment of poor graft function after hematopoietic stem cell transplantation in children
10.1111/petr.14010 · 2021 · External reference
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study
10.1007/s12185-021-03153-3 · 2021 · External reference
Mesenchymal stromal cells enhance the engraftment of hematopoietic stem cells in an autologous mouse transplantation model
10.1186/s13287-015-0155-5 · 2015 · External reference
Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis
10.3389/fimmu.2023.1106464 · 2023 · External reference
Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience
10.3389/fped.2024.1375493 · 2024 · External reference
CD3+TCRαβ/CD19+-depleted stem cell boost and CD45RO+ memory T-cell add-back as a successful salvage treatment for poor graft function unresponsive to eltrombopag, following a second allogenic HSCT
10.1002/pbc.31203 · 2024 · External reference
